Join the Lymphoma group to help and get support from people like you.
Lymphoma News (Page 2)
Related terms: Cancer, Lymphoma
Liso-Cel Cost-Effective for Second-Line Relapsed/Refractory Lymphoma
THURSDAY, Jan. 4, 2024 – Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy,...
American Society of Hematology, Dec. 9 to 12
The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical...
ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients
TUESDAY, Dec. 12, 2023 – For patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy...
Poor Physical Function Persists in Childhood Cancer Survivors
MONDAY, Nov. 20, 2023 – Despite changes in therapy, the prevalence of poor physical function has remained steady among childhood survivors of acute lymphoblastic leukemia (ALL) and non-Hodgkin...
Major Study Confirms CT Scans' Link to Blood Cancer Risk in Kids
FRIDAY, Nov. 10, 2023 – CT scans are significantly linked to an increased risk of blood cancers in young people, a major multinational study has found. Analysis of data from nearly 1 million people...
Birth Defects More Common in Babies Born to Moms Who've Had Cancer
TUESDAY, Oct. 10, 2023 – Teens and young adult women who survive cancer appear to have higher odds of delivering babies with birth defects, according to a new study. Knowing this, young women making...
Bariatric Surgery Linked to Reduced Incidence of Hematologic Cancer
WEDNESDAY, Sept. 27, 2023 – Bariatric surgery is associated with reduced incidence of hematological cancer, especially for women, according to a study published online Sept. 13 in The Lancet Healthy...
Weight-Loss Surgery Could Lower Odds for Blood Cancers
MONDAY, Sept. 25, 2023 – Weight-loss surgery can deliver a host of health benefits, but new research reveals an unexpected one: Getting the surgery was associated with a 40% lower risk of blood...
Fracking Tied to Lymphomas, Asthma in New Study
WEDNESAY, Aug. 16, 2023 – Research into a possible link between childhood health problems and natural gas wells in western Pennsylvania is wrapping up with some answers. Children who lived near...
Calquence Tablet Formulation Approved in the US Across Current indications
New formulation can be co-administered with gastric acid-reducing agents Tablet offers equivalent efficacy, safety and consistent dosing compared to current capsule 5 August 2022 – AstraZeneca’s n...
FDA Medwatch Alert: Drug Safety Communication: Copiktra (duvelisib) - FDA Warns about Possible Increased Risk of Death and Serious Side Effects
ISSUE: The FDA is warning that results from a clinical trial show a possible increased risk of death with Copiktra (duvelisib) compared to another medicine to treat a chronic blood cancer called...
FDA Medwatch Alert: FDA Approval of Lymphoma Medicine Ukoniq (umbralisib) is Withdrawn Due to Safety Concerns
June 1, 2022 – Due to safety concerns, the U.S. Food and Drug Administration (FDA) has withdrawn its approval for the cancer medicine Ukoniq (umbralisib). Ukoniq was approved to treat two specific...
Yescarta Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
SANTA MONICA, Calif.--(BUSINESS WIRE)--Apr. 1, 2022-- Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ...
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta Showing Prophylactic Steroid Use Improves Management of Cytokine Release Syndrome
SANTA MONICA, Calif.--(BUSINESS WIRE)--Jan. 31, 2022-- Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved an update to the prescribing...
U.S. FDA Grants Brukinsa (zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE) September 15, 2021 – BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Non-Hodgkin's Lymphoma, Blood Disorders